Log in or Sign up for Free to view tailored content for your specialty!
Neurorehabilitation News
Phase 2 trial of therapeutic for anxiety initiated
A Southern California-based neuroscience company has announced initiation of a phase 2 clinical trial to evaluate the safety and efficacy of investigational therapeutic ENX-102 in those with generalized anxiety disorder.
Orphan drug designation sought for stem cell therapy to treat frontotemporal dementia
Therapeutic Solutions International has filed with the FDA to receive orphan drug designation for its JadiCell adult stem cell therapy for treatment of frontotemporal dementia.
Log in or Sign up for Free to view tailored content for your specialty!
Neurologist partners with PCPs to elevate care for patients with mental illness
We are in a crisis when it comes to mental health in Alabama. According to the National Alliance on Mental Health, one in five adults in the state lives with mental illness.
Finger prick test detects blood-based biomarkers of Alzheimer’s disease
A finger prick test measured blood-based biomarkers of Alzheimer’s disease and has potential to increase accessibility of testing, according to research at the Alzheimer’s Association International Conference.
AbbVie committed to extending clinical value of its therapeutics
BOSTON — With a multitude of products spanning neuroscience and psychiatry, executives at AbbVie say they are committed to learning the full clinical value of all of the company’s products for the benefit of patients.
Repetitive head injuries, time played linked to CTE severity in football-playing males
In football-playing males, the number and force of repetitive head injuries as well as time playing the sport were linked to severity of chronic traumatic encephalopathy, according to research published in Nature Communications.
Positive 12-month results reported in study of Becker muscular dystrophy therapeutic
Edgewise Therapeutics Inc. announced positive 12-month topline results from the ARCH study evaluating the safety, tolerability and pharmacokinetics of EDG-5506 in adults with Becker muscular dystrophy.
Skyclarys now available to patients with Friedreich’s ataxia
Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years who have Friedreich’s ataxia, a rare degenerative neuromuscular disorder that manifests at a young age.
FDA approves Rystiggo for adults with generalized myasthenia gravis
The FDA has approved Rystiggo, a subcutaneous infusion therapy to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.
FDA approves Elevidys for pediatric Duchenne muscular dystrophy
The FDA has approved Elevidys, a recombinant gene therapy for pediatric patients with Duchenne muscular dystrophy and confirmed gene mutation who do not have a pre-existing medical reason preventing treatment.